menu
ALLOTCBB Top Rated Top Upgraded Most Active Gainers Losers

PROVECTUS BIOPHARM (PVCT)
0.0604 0.018 (43.81%)  12-14 16:00
Open: 0 Prev Close: 0.042
High: 0 Low: 0
Volume: 0 Market Cap: 22M
Year High: 0.077 Year Low: 0
Stock Technical Analysis
Overall       
Targets Six months: 0.0899    One year: 0.1050
Supports Support1: 0.0449   Support2: 0.0250
Resistances Resistance1: 0.0770    Resistance2: 0.0899 
Pivot Point 0.0406 
Moving Averages MA(5): 0.0443      MA(20): 0.0402 

MA(100): 0.0326  1     MA(250): 0.0327 
MACD MACD(12,26): 0.003      Signal(12,26,9): 0.001 
Stochastic Oscillator %K(14,3): 80.017      %D(3): 79.759 
RSI RSI(14): 80.252 
52-Week High: 0.0770  Low: 0.0110  Change(%): 331
Average Volume(K) 3-Month: 74401  10-Days: 129416
Moving Averages analysis
Price and moving averages has closed above its Short term moving average. Short term moving average is above its mid-term; and above long term moving averages. From the relationship between price and moving averages; we can see that: this stock is BULLISH in short-term; and BULLISH in mid-long term.
Bollinger Bands Analysis
Bollinger Bands has closed Bollinger Bands are 138.4% wider than normal.The large width of the bands suggest high volatility as compared to PVCT's normal range. The bands have been in this wide range for 0 bars. This is often a sign that the current trend may be ending.

Stoxline

Stock Chart

Top 100 stocks

Stock News
PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT ...
Thu, 14 Dec 2017 10:52:30 GMT

PROVECTUS Announces Resolution of SEC Investigation
Tue, 12 Dec 2017 21:11:15 GMT

Provectus Biopharmaceuticals Inc.
Thu, 14 Apr 2011 17:28:02 GMT

PROVECTUS BIOPHARMACEUTICALS RECEIVES SECOND CANCER COMBINATION THERAPY PATENT ...
Tue, 07 Nov 2017 21:00:00 GMT

Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering ...
Tue, 31 Jan 2017 12:56:15 GMT

Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
Fri, 10 Feb 2017 23:37:30 GMT

Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment
Thu, 23 Mar 2017 21:56:18 GMT

Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Wed, 28 Dec 2016 22:07:30 GMT

PROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED ...
Mon, 23 Oct 2017 12:00:00 GMT

Provectus Biopharmaceuticals Announces Data on PV-10 for Treatment of ...
Wed, 02 Nov 2016 09:56:15 GMT